Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 28, Issue 3, 2001, Pages 299-319

  Mentre F ^a   Dubruc, C ^b,c   Thenot J P ^b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SANOFI   (France)

^c Synthélabo ^*  (France)

Author keywords

Mizolastine; Optimal design; Pediatrics; Pharmacokinetics; Population analysis

Indexed keywords

MIZOLASTINE;

ALLERGIC RHINITIS; ARTICLE; CHILD; DRUG ABSORPTION; DRUG DESIGN; EUROPE; HUMAN; HUMAN EXPERIMENT; POPULATION RESEARCH; PRIORITY JOURNAL; REFERENCE VALUE; REGRESSION ANALYSIS; STANDARDIZATION; VOLUNTEER;

ADULT; BENZIMIDAZOLES; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MODELS, CHEMICAL; NONLINEAR DYNAMICS; RESEARCH DESIGN; SOLUTIONS;

EID: 0034953568     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011583210549     Document Type: Article

References (15)

1. Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses: Noncompartmental approach and compartmental modeling
2. Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method
3. Optimal design in random-effects regression models
4. Sparse-sampling optimal designs in pharmacokinetics and toxicokinetics
5. Robust optimal design for the estimation of hyperparameters in population pharmacokinetics
6. Population pharmacokinetics of an oral solution of mizolastine, a new anti-histamine, in children
7. An algorithm for least squares estimation of nonlinear parameters
8. NONMEM Users Guides, Version 5, NONMEM Project Group
9. Alternative approaches to estimation of population pharmacokinetic parameters with the nonlinear mixed effect model
10. Optimum Experimental Design
11. The sequential generation of D-optimum experimental designs
12. Conjugation reactions in the newborn infant: The metabolism of para-aminobenzoic acid
13. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients, 21 CFR Parts 201, 312, 314, and 601
14. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs